Abstract
Metronidazole and its two principal oxidative metabolites were tested in vitro against 20 clinical isolates of the Bacteroides fragilis group. Both metabolites were bactericidal, and the exhibited 65 and 5%, respectively, of the inhibitory effect of metronidazole. Additive or weak synergistic effects resulted in combination with the parent compound.